8-K: Know Labs Launches Technology Licensing Division to Monetize RFDS Platform

Know Labs has announced the formation of Know Labs Technology Licensing (KTL) to monetize its radio frequency dielectric spectroscopy (RFDS) technology across various industries.

Summary

• Know Labs has established a new business unit called Know Labs Technology Licensing (KTL).
• KTL will focus on licensing Know Labs' intellectual property portfolio to corporate partners, academic institutions, and research organizations.
• This initiative aims to expand the adoption of Know Labs' RFDS technology beyond medical diagnostics.
• KTL is modeled after the Qualcomm Technology Licensing (QTL) framework.
• The company intends to generate licensing revenues and establish RFDS as an industry standard.
• Know Labs will provide Software Development Kits (SDKs) and test automation products to its licensing partners.
• The company's initial focus remains on non-invasive medical diagnostics, particularly blood glucose monitoring.
• KTL will explore applications in industrial processes, consumer electronics, automotive, and IoT networks.
• The formation of KTL was prompted by significant third-party interest in the company's RFDS technology.
• An early example of KTL's work is a program to commercialize a smart steering wheel for automotive safety.

Sentiment

Score: 8

Explanation: The document presents a positive development for Know Labs, with the launch of a new business unit focused on monetizing its technology. The company is responding to market demand and expanding its potential revenue streams. The comparison to Qualcomm's licensing model is also a positive indicator.

Positives

• The formation of KTL allows Know Labs to monetize its intellectual property and generate new revenue streams.
• Expanding the application of RFDS technology into diverse industries increases the potential market for Know Labs' technology.
• The licensing model allows for collaborative innovation and faster adoption of the technology.
• The company is responding to unsolicited inbound demand, indicating strong market interest in its technology.
• The company is providing SDKs and test automation products to partners, which should accelerate adoption.

Negatives

• The company is still reliant on the success of its core medical diagnostic applications, particularly blood glucose monitoring.
• The success of KTL is dependent on the ability to secure licensing agreements and generate revenue from these agreements.
• The company is entering new markets where it may not have established expertise or relationships.

Risks

• The success of KTL depends on the ability to secure licensing agreements and generate revenue.
• The company faces competition in the various industries it is targeting with its RFDS technology.
• The company's core medical diagnostic applications, particularly blood glucose monitoring, still require FDA clearance.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

Know Labs aims to generate licensing revenues through KTL and establish RFDS as an industry standard, while continuing to focus on its core medical diagnostic applications. The company expects to see collaborative innovation in industries beyond medical diagnostics.

Management Comments

• Ron Erickson, CEO and Chairman at Know Labs, stated that the launch of KTL is a bold step forward to amplify the reach and impact of their RFDS platform.
• Erickson also mentioned that the breadth and scale of opportunities presented to them requires an open model of collaboration between corporate partners and leading academic research institutions.
• Erickson noted that the formation of KTL was prompted by a large number of third parties expressing interest in exploring potential applications for their RFDS technology.

Industry Context

This announcement reflects a trend of technology companies seeking to monetize their intellectual property through licensing agreements. The move to expand the application of RFDS technology beyond medical diagnostics aligns with the growing interest in sensor technology across various industries, including automotive, consumer electronics, and industrial processes. The comparison to Qualcomm's licensing model suggests a desire to establish a similar level of industry influence and revenue generation.

Comparison to Industry Standards

• Know Labs is explicitly modeling its KTL division after Qualcomm Technology Licensing (QTL), which is a well-established and successful licensing program in the technology industry.
• Qualcomm's QTL division generates significant revenue by licensing its mobile technology patents to various manufacturers.
• Know Labs aims to replicate this success by licensing its RFDS technology across diverse sectors.
• While Qualcomm focuses on mobile and wireless technologies, Know Labs is targeting a broader range of applications, including medical, industrial, and automotive.
• The success of KTL will depend on its ability to secure licensing agreements and generate revenue comparable to industry benchmarks set by companies like Qualcomm.

Stakeholder Impact

• Shareholders may benefit from increased revenue streams and the potential for higher valuation.
• Employees may have new opportunities in the KTL division.
• Customers in various industries may gain access to innovative RFDS technology.
• Suppliers may see increased demand for components and services related to RFDS technology.
• Creditors may view the company more favorably due to the potential for increased revenue.

Next Steps

• Know Labs will focus on securing licensing agreements for its RFDS technology.
• The company will provide Software Development Kits (SDKs) and test automation products to its licensing partners.
• KTL will explore applications of RFDS technology in various industries, including industrial processes, consumer electronics, automotive, and IoT networks.
• The company will continue to develop its core medical diagnostic applications, particularly blood glucose monitoring.

Key Dates

Keywords

RFDS, Technology Licensing, Intellectual Property, Radio Frequency Spectroscopy, Non-Invasive Diagnostics, Medical Devices, Automotive, IoT, Licensing Revenue, Software Development Kits